EUVIMEDEUVIMED entdecken
Crossref

Revisiting coexisting chromosomal abnormalities in NPM1 -mutated AML in light of the revised ELN 2022 classification

Linus Angenendt iD, Christoph Röllig iD, Pau Montesinos iD, Farhad Ravandi, Gunnar Juliusson, Christian Récher iD, Raphaël Itzykson iD, Zdeněk Ráčil, Andrew H Wei iD, Christoph Schliemann

Blood · 26.01.2023 · 141 (4) · 433-435

DOI: 10.1182/blood.2022018582 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, erschienen am 26.01.2023. Verfasst von Linus Angenendt und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine A, Münster University Hospital, Münster, Germany. Hauptthemen laut MEDLINE: Chromosome Aberrations, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 6 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mutations in the nucleophosmin 1 gene (NPM1) occur frequently in acute myeloid leukemia (AML) and are associated with a favorable prognosis. Applying the new 2022 European LeukemiaNet (ELN) classifier, Angenendt et al tested the prognostic significance of the copresence of NPM1 mutations and adverse-risk cytogenetics among 2426 patients. The authors demonstrate that outcomes for cytogenetic adverse-risk AML are not modulated by the presence or absence of NPM1 mutations, thereby clarifying management for patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chromosome AberrationsLeukemia, Myeloid, AcuteHumansNuclear ProteinsMutationPrognosis

Substanzen

Nuclear Proteins

Autor:innen und Institutionen

  • Department of Medicine A, Münster University Hospital, Münster, Germany.
  • Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
  • Dresden University Hospital, Technical University Dresden, Dresden, Germany.
  • Hospital Universitari i Politècnic La Fe, Valencia, Spain.
  • Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.
  • The University of Texas MD Anderson Cancer Center, Houston, TX.

ORCID-Profile: Linus Angenendt, Christoph Röllig, Pau Montesinos, Christian Récher, Raphaël Itzykson, Andrew H Wei

Zitieren

APA

Angenendt, L., Röllig, C., Montesinos, P., Ravandi, F., Juliusson, G., Récher, C., Itzykson, R., Ráčil, Z., Wei, A. H., & Schliemann, C. (2023). Revisiting coexisting chromosomal abnormalities in NPM1 -mutated AML in light of the revised ELN 2022 classification. Blood, 141(4), 433-435. https://doi.org/10.1182/blood.2022018582

Vancouver

Angenendt L, Röllig C, Montesinos P, Ravandi F, Juliusson G, Récher C, et al. Revisiting coexisting chromosomal abnormalities in NPM1 -mutated AML in light of the revised ELN 2022 classification. Blood. 2023;141(4):433-435. doi:10.1182/blood.2022018582

BibTeX
@article{Angenendt2023,
  author = {Angenendt, Linus and Röllig, Christoph and Montesinos, Pau and Ravandi, Farhad and Juliusson, Gunnar and Récher, Christian and Itzykson, Raphaël and Ráčil, Zdeněk and Wei, Andrew H and Schliemann, Christoph},
  title = {Revisiting coexisting chromosomal abnormalities in NPM1 -mutated AML in light of the revised ELN 2022 classification},
  journal = {Blood},
  year = {2023},
  volume = {141},
  number = {4},
  pages = {433--435},
  doi = {10.1182/blood.2022018582}
}
Kostenlos starten →